AVITA Medical, Inc. (RCEL)
Health Care · Acute wound care and regenerative medicine devices · Nasdaq
A therapeutic wound care company commercializing RECELL, an autologous cell harvesting device that creates patient-derived skin cell suspension for treating burns and traumatic injuries, now expanding into a multi-product acute wound care platform.
What AVITA Medical, Inc. does
AVITA Medical is a therapeutic acute wound care company that develops and commercializes proprietary skin cell harvesting and wound closure technologies. The company's flagship product RECELL is an autologous cell harvesting device that enables clinicians to create a suspension of a patient's own skin cells (Spray-On Skin) at the point of care for treating burns, traumatic injuries, and surgical wounds. AVITA has expanded into a multi-product platform by distributing complementary wound care products including PermeaDerm (biosynthetic wound matrix) and Cohealyx (collagen-based dermal matrix).
Themes: ["autologous cell therapy / regenerative medicine","acute wound care / burn treatment","trauma and surgical wound management","dermal matrices / wound bed preparation","point-of-care medical devices"]
Fundamentals
- Price$4.06 as of 2026-07-10 close
- Market cap$125M as of 2026-07-13
- 1-year return-31.6% as of 2026-07-10 close
- Net margin-62.7% as of 2026-07-13
- Gross margin+82.1% as of 2026-07-13
- ROE-337.9% as of 2026-07-13
- Debt / equity9.39 as of 2026-07-13
- Revenue growth (YoY)+1.0% as of 2026-07-13
- Revenue CAGR (3y)+27.7% SEC XBRL
- Beta1.86 as of 2026-07-13
Key risks (from latest filing)
["Regulatory and reimbursement risks: dependence on FDA approvals and third-party payor coverage determinations for RECELL and complementary products; failure to obtain or maintain favorable coverage could materially impact revenue growth","Market adoption and competition: ability to expand market penetration in burn centers and trauma/surgical settings; increasing competition and need to scale commercial infrastructure to meet demand","Profitability and liquidity: significant operating losses (-62.67% net margin), flat revenue growth (0.96% YoY), and need to achieve positive cash flow and long-term profitability; covenant compliance risks on debt obligations"]
Competitors & peers
- Smith & Nephew
- Integra LifeSciences
- Baxter International (burn care)
- ConvaTec (wound care)
- Mimedx (skin grafts and matrices)
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.